Literature DB >> 25662696

[Rate and rhythm control in atrial fibrillation : pharmacological approaches].

K F Weipert1, D Erkapic, J Schmitt.   

Abstract

Atrial fibrillation is the most common form of cardiac arrhythmia, occurring in 1-2 % of the population and due to an increased life expectancy the prevalence will increase further. Pharmacological treatment of atrial fibrillation is an important component of basic initial therapeutic options for patients with atrial fibrillation. Independent of an individually adjusted prevention of thromboembolism, rate and rhythm management can also be carried out. While rate control mainly applies to all patients, rhythm control is only indicated in patients who remain clinically symptomatic despite sufficient rate control. Profound knowledge about antiarrhythmic drugs including specific interactions is necessary due to the variable individual effects and sometimes severe side effects.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25662696     DOI: 10.1007/s00059-014-4201-3

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  60 in total

1.  Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.

Authors:  Rangadham Nagarakanti; Michael D Ezekowitz; Jonas Oldgren; Sean Yang; Michael Chernick; Timothy H Aikens; Greg Flaker; Josep Brugada; Gabriel Kamensky; Amit Parekh; Paul A Reilly; Salim Yusuf; Stuart J Connolly
Journal:  Circulation       Date:  2011-01-03       Impact factor: 29.690

2.  A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.

Authors:  A John Camm; Alessandro Capucci; Stefan H Hohnloser; Christian Torp-Pedersen; Isabelle C Van Gelder; Brian Mangal; Gregory Beatch
Journal:  J Am Coll Cardiol       Date:  2011-01-18       Impact factor: 24.094

3.  Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias.

Authors:  H F Clemo; M A Wood; D M Gilligan; K A Ellenbogen
Journal:  Am J Cardiol       Date:  1998-03-01       Impact factor: 2.778

4.  Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation.

Authors:  I A Khan
Journal:  J Am Coll Cardiol       Date:  2001-02       Impact factor: 24.094

5.  Amiodarone versus sotalol for atrial fibrillation.

Authors:  Bramah N Singh; Steven N Singh; Domenic J Reda; X Charlene Tang; Becky Lopez; Crystal L Harris; Ross D Fletcher; Satish C Sharma; J Edwin Atwood; Alan K Jacobson; H Daniel Lewis; Dennis W Raisch; Michael D Ezekowitz
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

6.  Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study.

Authors:  S Stewart; C L Hart; D J Hole; J J McMurray
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

Review 7.  Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.

Authors:  Irene Savelieva; Richard Graydon; A John Camm
Journal:  Europace       Date:  2013-10-09       Impact factor: 5.214

Review 8.  Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.

Authors:  C Lafuente-Lafuente; S Mouly; M A Longas-Tejero; J F Bergmann
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

9.  Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome--a case-control pilot study using i.v. sotalol.

Authors:  Stefan Kääb; Martin Hinterseer; Michael Näbauer; Gerhard Steinbeck
Journal:  Eur Heart J       Date:  2003-04       Impact factor: 29.983

10.  European Heart and Rhythm Association guidelines on new oral anticoagulants: A bold step forward.

Authors:  Vishal Sehgal; Sukhminder Jit Singh Bajwa
Journal:  J Pharmacol Pharmacother       Date:  2014-04
View more
  2 in total

1.  Compensatory caspase activation in MPP+-induced cell death in dopaminergic neurons.

Authors:  J L Y Chee; X L Guan; J Y Lee; B Dong; S M Leong; E H Ong; A K F Liou; T M Lim
Journal:  Cell Mol Life Sci       Date:  2005-01       Impact factor: 9.261

Review 2.  [Current state of treatment strategies for atrial fibrillation].

Authors:  C Rogge; S Hilbert; N Dagres; G Hindricks
Journal:  Herz       Date:  2016-05       Impact factor: 1.443

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.